AI assistant

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

IONIS PHARMACEUTICALS INC Director's Dealing 2025

Mar 4, 2025

30591_dirs_2025-03-04_70edf897-346d-4314-87cc-7520921880e2.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: IONIS PHARMACEUTICALS INC (IONS)
CIK: 0000874015
Period of Report: 2025-02-28

Reporting Person: Swayze Eric (EVP Research)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2025-02-28	Common Stock	J	415	$28.2115	Acquired	48432	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	184	Indirect

Footnotes

F1: Reporting shares purchased under the Ionis Pharmaceuticals, Inc. Amended and Restated 2000 Employee Stock Purchase Plan on February 28,2025. These shares may not be sold until August 28, 2025.